Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Unique Effects of Clozapine: A Pharmacological Perspective
Jibran Y. Khokhar, Angela M. Henricks, Emily D. K. Sullivan, et al.
Advances in pharmacology (2018), pp. 137-162
Open Access | Times Cited: 152

Showing 1-25 of 152 citing articles:

Prevention of suicide by clozapine in mental disorders: systematic review
Vasilios G. Masdrakis, David S. Baldwin
European Neuropsychopharmacology (2023) Vol. 69, pp. 4-23
Open Access | Times Cited: 47
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment
Qibo Huang, Bai Hu, Zhang Ping, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Drug development in psychiatry: 50 years of failure and how to resuscitate it
David Nutt
The Lancet Psychiatry (2025)
Closed Access | Times Cited: 2
Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
Domenico De Berardis, Michele Fornaro, Alessandro Valchera, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 2888-2888
Open Access | Times Cited: 159
Phagocytosis, Degranulation and Extracellular Traps Release by Neutrophils—The Current Knowledge, Pharmacological Modulation and Future Prospects
Barbara Gierlikowska, Albert Stachura, Wojciech Gierlikowski, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 82
Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
Minghuan Zhu, Zhen-Jing Liu, Qiong-Yue Hu, et al.
Military Medical Research (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 54
Finding new and better treatments for psychiatric disorders
Steven M. Paul, William Z. Potter
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 3-9
Open Access | Times Cited: 35
Separation and Quantitative Estimation of Pharmacopeial Organic Impurities, Process‐Related Impurities, and Degradation Products of the Anti‐Schizophrenia Drug Clozapine in Pharmaceutical Formulations by Using Stability‐Indicating HPLC Method
Abhishek Sharma, Pedavenkatagari Narayana Reddy, Bhujanga Rao Nagulancha, et al.
Biomedical Chromatography (2025) Vol. 39, Iss. 3
Open Access | Times Cited: 1
COVID-19 disease outcomes in patients receiving clozapine versus other antipsychotics: a national study in Qatar
Dalia Albahari, Oraib Abdalla, Shatha Mahmud Ismail Alqam, et al.
Frontiers in Psychiatry (2025) Vol. 16
Open Access | Times Cited: 1
Alcohol Use Disorder and Schizophrenia and Schizoaffective� Disorders
Luke J. Archibald
Alcohol research (2019) Vol. 40, Iss. 1
Open Access | Times Cited: 73
Polypharmacy in schizophrenia
Lone Baandrup
Basic & Clinical Pharmacology & Toxicology (2020) Vol. 126, Iss. 3, pp. 183-192
Open Access | Times Cited: 68
Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
Heidi Taipale, Markku Lähteenvuo, Antti Tanskanen, et al.
Schizophrenia Bulletin (2020) Vol. 47, Iss. 1, pp. 23-30
Open Access | Times Cited: 61
Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals
Robert J. Flanagan, John Lally, Siobhan Gee, et al.
British Medical Bulletin (2020) Vol. 135, Iss. 1, pp. 73-89
Open Access | Times Cited: 55
Clozapine: Why Is It So Uniquely Effective in the Treatment of a Range of Neuropsychiatric Disorders?
Dara Gammon, Catherine Cheng, Anna Volkovinskaia, et al.
Biomolecules (2021) Vol. 11, Iss. 7, pp. 1030-1030
Open Access | Times Cited: 53
Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug
Liliana Dell’Osso, Chiara Bonelli, Benedetta Nardi, et al.
Brain Sciences (2024) Vol. 14, Iss. 1, pp. 103-103
Open Access | Times Cited: 7
Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia
Samskruthi Madireddy, Sahithi Madireddy
Brain Sciences (2020) Vol. 10, Iss. 10, pp. 742-742
Open Access | Times Cited: 40
Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19
Ana Miruna Drăgoi, I.D. Rădulescu, Bogdana Adriana Năsui, et al.
Brain Sciences (2020) Vol. 10, Iss. 11, pp. 840-840
Open Access | Times Cited: 35
Dried Volumetric Microsampling Approaches for the Therapeutic Drug Monitoring of Psychiatric Patients Undergoing Clozapine Treatment
Camilla Marasca, Roberto Mandrioli, Roccaldo Sardella, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 21
Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: A nationwide cohort study in Taiwan
Wen‐Yin Chen, Pao‐Huan Chen, Chun‐Hung Pan, et al.
Schizophrenia Research (2023) Vol. 268, pp. 150-160
Closed Access | Times Cited: 13
Variation of Clozapine Use for Treatment of Schizophrenia: Evidence from Pennsylvania Medicaid and Dually Eligible Enrollees
Deepak K. Sarpal, Evan S. Cole, Jessica M. Gannon, et al.
Community Mental Health Journal (2024) Vol. 60, Iss. 4, pp. 743-753
Closed Access | Times Cited: 4
The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review
Petru Fabian Lungu, Corina-Miruna Lungu, Alin Ciobîcă, et al.
Brain Sciences (2024) Vol. 14, Iss. 4, pp. 359-359
Open Access | Times Cited: 4
Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine
Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Nicholas Aderinto, et al.
Journal of Integrative Neuroscience (2024) Vol. 23, Iss. 4, pp. 80-80
Open Access | Times Cited: 4
Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia
Joseph T. Coyle
Biochemical Pharmacology (2024) Vol. 228, pp. 116376-116376
Closed Access | Times Cited: 4
Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
Stefania Chiappini, Fabrizio Schifano, John Corkery, et al.
Brain Sciences (2020) Vol. 10, Iss. 2, pp. 105-105
Open Access | Times Cited: 28
Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder
Alberto Forte, Maurizio Pompili, Benedetta Imbastaro, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 9, pp. 1074-1080
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top